GluBio Therapeutics
Hangzhou · Founded 2021
About GluBio Therapeutics
GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.
Company Facts
- Founded: 2021
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $102.0M
- Last round: Corporate Round (Feb 2026)
- Website: https://www.glubiotx.com
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/glubio-therapeutics-83206 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.